Segment Information (Tables)

3 Months Ended

Mar. 31, 2025

Segment Reporting [Abstract]

Summary of Company's Financial Data for Development and Commercialization of Pharmaceutical Products Segment

The following table summarizes the Company’s financial data for its development and commercialization of pharmaceutical products segment:

	Three Months Ended March 31,
	2025			2024
Net product sales	$	3,080,158		$	1,735,490
Less:
Cost of goods sold		(41,613	)		(92,529	)
Eversana profit sharing		(2,618,135	)		(1,475,261	)
Employee expenses		(638,099	)		(696,801	)
Professional fees		(704,629	)		(503,717	)
Stock-based compensation		(84,384	)		(254,029	)
Sales and marketing expenses		(188,668	)		(163,797	)
Other operating expenses(1)		(106,373	)		(50,576	)
Interest income		118,853			46,058
Interest expense (non-cash)		(123,288	)		(124,658	)
Total segment costs loss and net loss	$	(1,306,178	)	$	(1,579,820	)

________________

(1) Includes ongoing product development costs, occupancy costs (including rent and utilities), administrative costs, travel and business taxes.